Trevi Therapeutics, Inc. Common Stock (TRVI)
PHARMACEUTICAL PREPARATIONS
Trevi Therapeutics, Inc. Common Stock (TRVI) is listed on Nasdaq, where it has traded since May 3, 2019.
- Listed On
- Nasdaq
- Listed Since
- May 3, 2019
- Employees
- 34
- Market Cap
- $1.9B
About Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 212 institutions reported holding TRVI, with 149.0 million shares worth $2.8 billion in aggregate. The largest reported holder was Nea Management Company, with 13.2 million shares worth $246.6 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Nea Management Company | 13,222,228 | $247M | Unchanged |
| FMR | 12,562,839 | $234M | Added 56.29% |
| BlackRock | 11,155,026 | $208M | Added 8.93% |
| Frazier Life Sciences Management | 9,939,447 | $185M | Reduced |
| Vanguard | 7,710,300 | $144M | Added 13.47% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TRVI?
Trevi Therapeutics, Inc. Common Stock (TRVI) is listed on Nasdaq, where it has traded since May 3, 2019.
Who are the largest institutional holders of TRVI?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TRVI were Nea Management Company, FMR and BlackRock.
How many institutions own TRVI?
212 institutions reported a position in TRVI for the quarter ended June 30, 2026, worth $2.8 billion in total.
Did institutions buy or sell TRVI last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TRVI.
Every reported institutional holder, plus insider and congressional trades in TRVI, on SentiSense.